Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.11 | -0.07 | 0.29 |
| FCF Yield | -107.83% | -165.89% | -19.16% | -3.67% |
| EV / EBITDA | 0.70 | -0.04 | -2.24 | -11.57 |
| Quality | ||||
| ROIC | -25.53% | -54.06% | -37.49% | -12.44% |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.94 | 0.79 | 0.78 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | – | -73.77% |
| Free Cash Flow Growth | 0.00% | 8.08% | -89.67% | -64.65% |
| Safety | ||||
| Net Debt / EBITDA | 1.50 | 0.48 | 2.13 | 3.79 |
| Interest Coverage | 6,883.75 | -37.36 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |